229 patents
Page 2 of 12
Utility
Targeting dimerization of BAX to modulate BAX activity
19 Sep 23
Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX.
Evripidis Gavathiotis
Filed: 19 Mar 19
Utility
Inhibition of Bax-mediated Cell Death by Eltrombopag
31 Aug 23
This disclosure provides methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as methods for treating or preventing BAX-mediated disorders, based, in part, on an unexpected discovery that eltrombopag (EO) can work as as a potent binder to the BAX trigger site and an effective direct BAX inhibitor.
Evripidis Gavathiotis
Filed: 15 Apr 21
Utility
Methods of treatment by targeting VCAM1 and MAEA
22 Aug 23
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
Paul S. Frenette, Sandra Pinho, Qiaozhi Wei
Filed: 1 Oct 20
Utility
Methods and Compositions for Assessing Germline Risk of Cancer
17 Aug 23
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers.
Harry OSTRER, Johnny C. LOKE, Alexander PEARLMAN
Filed: 6 Apr 23
Utility
Methods and devices for intraoperative viewing of patient 3D surface images
15 Aug 23
Methods and devices are disclosed for intra-operative viewing of pre- and intra-operative 3D patient images.
Oren Mordechai Tepper, Jillian Schreiber, Cesar Colasante
Filed: 2 Oct 20
Utility
PXR agonists and uses thereof for gut barrier dysfunction treatment and prevention
15 Aug 23
Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.
Sridhar Mani, Felix Kopp, Zdenek Dvorak, Sandhya Kortagere, Chamini Karunaratne
Filed: 18 Jan 18
Utility
High resolution intravital imaging and uses thereof
1 Aug 23
Methods and apparatus are provided for high resolution intravital imaging and for chronic optical imaging of tissues such as lung.
David Entenberg, John S. Condeelis, Sonia E. Voiculescu
Filed: 1 Aug 18
Utility
Immunoregulatory role of 3-OH-kynurenamine and uses thereof
1 Aug 23
Methods are provided for using 3-OH-kynurenamine to treat and prevent an inflammatory or autoimmune disease or disorder or transplant rejection, and for promoting immune tolerance.
Laura Santambrogio
Filed: 12 Mar 19
Utility
Characterization of S-adenosyl-l-methionine-consuming Enzymes with 1-STEP Ez-mtase: a Universal Coupled-assay
13 Jul 23
Methods and kits are disclosed for measuring activity of a methyltransferase or a radical SAM enzyme or for screening for an inhibitor of a methyltransferase or a radical SAM enzyme, where the methods and kits comprise, respectively, deaminase TM0936 for a MTase coupled assay and deaminase PA3170 for a radical SAM coupled assay.
Emmanuel Sebastien BURGOS, David SHECHTER
Filed: 20 Feb 18
Utility
Methods of Treatment by Targeting VCAM1 and Maea
6 Jul 23
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
Paul S. FRENETTE, Sandra PINHO, Qiaozhi WEI, Sung Kyun LEE
Filed: 27 Dec 22
Utility
Methods of using HSV-2 single cycle virus delta-gD and HSV-2 recombinant glycoprotein D
27 Jun 23
Methods of vaccinating, immunizing and/or treating a subject against a herpes simplex virus infection or a disease caused by a herpes simplex virus infection comprise administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D, wherein the HSV-2 single-cycle virus comprises HSV-2 having a deletion of glycoprotein D-encoding gene in the genome and the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D on a lipid bilayer of the HSV-2.
Betsy C. Herold, Clare Burn Aschner
Filed: 1 Jun 21
Utility
Methods and compositions for assessing germline risk of cancer
16 May 23
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers.
Harry Ostrer, Johnny C. Loke, Alexander Pearlman
Filed: 12 Jun 20
Utility
High-affinity
9 May 23
Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.
Jacqueline M. Achkar, Jonathan Lai, Elise Ishida, Daniel Hofmann, Tingting Chen
Filed: 15 Dec 20
Utility
Omega Muricholic Acid As a Pregnane X Receptor Ligand for Treating Hepato-intestinal Diseases
27 Apr 23
Methods for activating pregnane X receptor (PXR) using co-muricholic acid thereby treating metabolic syndrome, obesity, inflammatory bowel disease, Crohn’s disease, and liver disease, and also thereby increasing CYP3A4 gene and/or protein expression.
Julia Yue Cui, Sridhar Mani, Moumita Dutta
Filed: 21 Oct 22
Utility
a Method to Generate Chimeric Antigen Receptor (Car) T-cells (Car-t Cells) from Pathogen-specific Cytotoxic Lymphocytes to Enable the Subsequent In Vivo Modulation of Their Functional Activity
27 Apr 23
The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.
Harris GOLDSTEIN, Steven C ALMO, Scott GARFORTH, Mengyan LI
Filed: 8 Mar 21
Utility
Transdermal Delivery Formulations
20 Apr 23
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 31 Oct 22
Utility
ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF
13 Apr 23
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Xingxing ZANG
Filed: 29 Jun 22
Utility
Method of Treating and Preventing Ocular Disease with HSV-2 Delta GD
13 Apr 23
Methods of treating or preventing ocular disease caused by herpes simplex virus-1 infection are provided, and comprise administering to a subject an effective amount of a herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome to treat or prevent ocular disease in the subject, wherein the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D by propagating the HSV-2 in a complementing cell expressing the HSV-1 glycoprotein D.
Betsy C. Herold
Filed: 7 Apr 21
Utility
HHLA2 As a Novel Inhibitor of Human Immune System and Uses Thereof
9 Mar 23
Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
Xingxing ZANG
Filed: 15 Sep 22
Utility
Stem cell-produced microvesicles for treating tendon pathologies
7 Mar 23
Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment.
Hui B. Sun
Filed: 21 Aug 17